Harlan Robins Sells 100,000 Shares of Adaptive Biotechnologies (NASDAQ:ADPT) Stock

Adaptive Biotechnologies Corporation (NASDAQ:ADPT) insider Harlan Robins sold 100,000 shares of the business’s stock in a transaction on Monday, June 15th. The stock was sold at an average price of $17.37, for a total value of $1,737,000.00. Following the completion of the sale, the insider directly owned 1,412,058 shares in the company, valued at $24,527,447.46. This trade represents a 6.61% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Adaptive Biotechnologies Price Performance

Shares of NASDAQ:ADPT opened at $17.54 on Friday. Adaptive Biotechnologies Corporation has a 1-year low of $9.96 and a 1-year high of $20.76. The business has a fifty day moving average price of $14.80 and a 200-day moving average price of $15.57. The company has a market capitalization of $2.81 billion, a PE ratio of -53.16 and a beta of 2.15.

Adaptive Biotechnologies (NASDAQ:ADPT) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.16) by $0.03. The firm had revenue of $70.87 million during the quarter, compared to analyst estimates of $61.03 million. Adaptive Biotechnologies had a negative return on equity of 40.06% and a negative net margin of 16.82%.Adaptive Biotechnologies’s quarterly revenue was up 35.1% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.20) EPS. On average, sell-side analysts anticipate that Adaptive Biotechnologies Corporation will post -0.47 earnings per share for the current fiscal year.

Key Adaptive Biotechnologies News

Here are the key news stories impacting Adaptive Biotechnologies this week:

• Positive Sentiment: BTIG Research reaffirmed its Buy rating on Adaptive Biotechnologies and set a $22 price target, implying upside from recent trading levels.
• Positive Sentiment: The company said part of the convertible-note proceeds will be used for a $25 million stock repurchase and capped-call transactions, which may help offset dilution risk.
• Neutral Sentiment: The notes carry an initial conversion price of about $24.11 per share, which is well above the recent share price and suggests management is trying to limit near-term dilution.
• Negative Sentiment: Adaptive Biotechnologies priced an upsized $300 million convertible debt deal, up from $250 million, which some investors may read as a larger-than-expected financing need.
• Negative Sentiment: Insider selling also weighed on sentiment: Chief Scientific Officer Harlan S. Robins sold 106,160 shares in recent transactions, and the recent insider activity has been entirely sales.

Institutional Investors Weigh In On Adaptive Biotechnologies

Several hedge funds and other institutional investors have recently made changes to their positions in ADPT. California State Teachers Retirement System boosted its holdings in shares of Adaptive Biotechnologies by 1.0% in the second quarter. California State Teachers Retirement System now owns 98,321 shares of the company’s stock worth $1,145,000 after buying an additional 933 shares during the last quarter. PNC Financial Services Group Inc. grew its position in Adaptive Biotechnologies by 6.8% during the first quarter. PNC Financial Services Group Inc. now owns 14,737 shares of the company’s stock valued at $205,000 after buying an additional 941 shares during the period. Captrust Financial Advisors increased its holdings in Adaptive Biotechnologies by 7.6% during the second quarter. Captrust Financial Advisors now owns 15,762 shares of the company’s stock valued at $184,000 after buying an additional 1,119 shares during the last quarter. Assetmark Inc. increased its holdings in Adaptive Biotechnologies by 46.4% during the first quarter. Assetmark Inc. now owns 4,421 shares of the company’s stock valued at $61,000 after buying an additional 1,401 shares during the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. increased its holdings in Adaptive Biotechnologies by 26.0% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 7,419 shares of the company’s stock valued at $120,000 after buying an additional 1,532 shares during the last quarter. Hedge funds and other institutional investors own 99.17% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on the stock. Guggenheim reiterated a “buy” rating and issued a $21.00 target price on shares of Adaptive Biotechnologies in a research note on Wednesday, May 6th. Wall Street Zen downgraded shares of Adaptive Biotechnologies from a “buy” rating to a “hold” rating in a research report on Saturday, March 7th. Morgan Stanley decreased their price objective on shares of Adaptive Biotechnologies from $21.00 to $18.00 and set an “equal weight” rating for the company in a report on Tuesday, May 12th. BTIG Research reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Adaptive Biotechnologies in a research report on Wednesday. Finally, JPMorgan Chase & Co. cut their target price on Adaptive Biotechnologies from $21.00 to $19.00 and set an “overweight” rating on the stock in a research note on Wednesday, May 6th. Five equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $20.33.

Adaptive Biotechnologies Company Profile

Adaptive Biotechnologies is a clinical-stage biotechnology company that focuses on harnessing the adaptive immune system to transform the diagnosis and treatment of disease. Through proprietary immune receptor sequencing and analysis, the company decodes the genetic information of T-cell and B-cell receptors to identify signatures of immune response. Its core technology platform provides insights into immune-driven conditions, enabling more precise monitoring and targeted therapeutic development.

The company’s flagship product, immunoSEQ, offers high-throughput immune repertoire profiling for researchers and pharmaceutical partners.